FDA Perspectives: Designation of Regulatory Starting Materials in the Manufacturing of Drug Substances: Impact on ANDA Review Time - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Perspectives: Designation of Regulatory Starting Materials in the Manufacturing of Drug Substances: Impact on ANDA Review Time
The author describes how providing appropriate information about the API in the Common Technical Document can aid FDA's review of an abbreviated new drug application.

Pharmaceutical Technology
Volume 36, Issue 1, pp. 63-66

The starting material for the manufacturing process does not comply with the Agency's current definition of an appropriate regulatory starting material for an active pharmaceutical ingredient. Please declare appropriate starting material(s) from an earlier point in the process and provide complete information on the entire process in this Drug Master File. Alternatively you can provide the information shown below for the designated supplier:

A) The detailed synthetic route (including in-process controls, isolated intermediates, reagents/solvents, etc.) for the outsourced starting material OR a DMF # from the outsourced vendor should be provided.

NOTE: If a secondary DMF is referenced within a primary DMF, the ANDA review time will be impacted.

B) The full name and address of the manufacturing site, related phone/FAX, contact person, and email address should be provided.

NOTE: It is possible that the Office of Compliance will inspect the site. If issues are found then neither DMF will be in good standing with the FDA.

C) Extensive starting material specification requirements especially with regard to impurity carryover for both residual solvents and related compounds may be requested.

D) Updated Certificate of Analysis (COA) from the vendor and in-house COA for the starting material will be requested.

E) A commitment to notify the FDA if the starting material vendor changes or the process is modified in any way, and to provide again all the relevant information for any new vendor.

Fermentation-derived starting materials

For those manufacturers using starting materials resulting from a fermentation process, it is necessary to pay close attention to the specifications for the well-characterized organic materials used in the fermentation (i.e., starch, glucose, lactose, corn steep liquor, and soybean meal) (6). Inorganic starting materials should meet the same requirements as for chemical synthesis. The microorganism cultured should be properly identified including morphological, cultural, and biochemical characteristics. More details regarding fermentation processes can be found in the draft guidance on fermentation (6).

Plant- or animal-based starting materials

Starting materials from plant (e.g., thebaine) or animal (e.g., low molecular weight heparins [7]) sources should provide source and location of plant or animal (i.e., species and organ tissue used), storage and transportation conditions, drying conditions, and grinding conditions. Full disclosure of how the starting material is isolated, purified, and characterized will be required. Pre-approval inspections of the source locations may be required on a case-by-case basis.

When choosing an API supplier, ANDA applicants must weigh the quality and commercial aspects judiciously. The choice will have a direct impact on the review and approval times of submitted ANDAs. The choice of a high quality API is also integral to building quality into a proposed drug product as part of a quality-by-design approach. API quality is essential to development of a quality drug product, and API attributes should be considered as part of the QTPP (8). While the author has highlighted a number of points with respect to API starting material designation and process controls, this is by no means an exhaustive list of considerations when selecting a potential API supplier.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here